JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4.5
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Richard Vosser has maintained a Neutral rating on Molecular Partners (NASDAQ:MOLN) and reduced the price target from $6.6 to $4.5.

December 05, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on Molecular Partners and lowered the price target from $6.6 to $4.5.
The reduction in price target by a major analyst like JP Morgan suggests a bearish outlook on the stock's value, which could lead to a negative short term impact on the stock price. The Neutral rating indicates no change in the overall recommendation, but the lower price target may influence market perception negatively.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100